A novel six-CpGs signature predicts clinical outcome in glioblastomas

ABSTRACT: We aimed to identify a clinically useful biomarker using DNA methylation-based information to optimize the management of glioblastoma (GBM) patients. We identified a novel six-CpGs signature that predicts the clinical outcome in GBM. The methylation profiling of 79 GBM patients has been used as a validation cohort to demonstrate the performance and the robustness of the identified six-CpGs signature. The status of the “MGMT” biomarker, traditionally used by clinicians to predict survival in GBM, is also indicated per sample.

ORGANISM(S): Homo sapiens

SUBMITTER: Amandine Etcheverry 

PROVIDER: E-MTAB-4969 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress